Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Publication year range
1.
Am Heart J ; 231: 128-136, 2021 01.
Article in English | MEDLINE | ID: mdl-33045224

ABSTRACT

The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain. DESIGN: RIVER was an academic-led, multicenter, open-label, randomized, non-inferiority trial with blinded outcome adjudication that enrolled 1005 patients from 49 sites in Brazil. Patients with a bioprosthetic mitral valve and atrial fibrillation or flutter were randomly assigned (1:1) to rivaroxaban 20 mg once daily (15 mg in those with creatinine clearance <50 mL/min) or dose-adjusted warfarin (target international normalized ratio 2.0-30.); the follow-up period was 12 months. The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, major bleeding, valve thrombosis, systemic embolism, or hospitalization for heart failure. Secondary outcomes included individual components of the primary composite outcome, bleeding events, and venous thromboembolism. SUMMARY: RIVER represents the largest trial specifically designed to assess the efficacy and safety of a direct oral anticoagulant in patients with bioprosthetic mitral valves and atrial fibrillation or flutter. The results of this trial can inform clinical practice and international guidelines.


Subject(s)
Atrial Fibrillation/complications , Atrial Flutter/complications , Bioprosthesis , Factor Xa Inhibitors/therapeutic use , Heart Valve Prosthesis , Mitral Valve , Rivaroxaban/therapeutic use , Thrombosis/prevention & control , Administration, Oral , Aspirin/administration & dosage , Bioprosthesis/adverse effects , Brazil , Cause of Death , Creatinine/metabolism , Embolism , Factor Xa Inhibitors/administration & dosage , Factor Xa Inhibitors/adverse effects , Heart Valve Prosthesis/adverse effects , Hemorrhage/chemically induced , Hospitalization , Humans , Ischemic Attack, Transient , Rivaroxaban/administration & dosage , Rivaroxaban/adverse effects , Sample Size , Stroke , Surgical Procedures, Operative , Thrombosis/etiology , Treatment Outcome , Warfarin/administration & dosage , Warfarin/adverse effects , Warfarin/therapeutic use
2.
N Engl J Med ; 383(22): 2117-2126, 2020 11 26.
Article in English | MEDLINE | ID: mdl-33196155

ABSTRACT

BACKGROUND: The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS: In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months. RESULTS: A total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], -1.4 to 16.3; P<0.001 for noninferiority). Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in the rivaroxaban group and in 26 (5.1%) in the warfarin group (hazard ratio, 0.65; 95% CI, 0.35 to 1.20). The incidence of stroke was 0.6% in the rivaroxaban group and 2.4% in the warfarin group (hazard ratio, 0.25; 95% CI, 0.07 to 0.88). Major bleeding occurred in 7 patients (1.4%) in the rivaroxaban group and in 13 (2.6%) in the warfarin group (hazard ratio, 0.54; 95% CI, 0.21 to 1.35). The frequency of other serious adverse events was similar in the two groups. CONCLUSIONS: In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Bioprosthesis , Mitral Valve , Rivaroxaban/therapeutic use , Warfarin/therapeutic use , Aged , Anticoagulants/adverse effects , Atrial Fibrillation/complications , Atrial Fibrillation/mortality , Cardiovascular Diseases/epidemiology , Factor Xa Inhibitors/therapeutic use , Female , Hemorrhage/chemically induced , Humans , Male , Middle Aged , Rivaroxaban/adverse effects , Single-Blind Method , Stroke/prevention & control , Warfarin/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL